Novel anti-HER2 antibody–drug conjugates (ADCs), namely trastuzumab deruxtecan (T-DXd) and trastuzumab duocarmazine (SYD985), have demonstrated promising activity against breast cancer with low HER2 expression in early-phase clinical trials [6,7,8,9,10]. This evidence concerns the gene ERBB2 and breast cancer.